
ReproNovo has dosed the first participant in its phase 2 NORDIC study evaluating RPN-002, an investigational therapy designed to improve …

ReproNovo has appointed Mark Altmeyer as Chairman of the Board of Directors. Bringing over 35 years of experience to the …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

